Update: Lilly Makes $7bn Bid for in Vivo CAR-T Firm Kelonia

Why It Matters

The transaction accelerates Lilly’s entry into next‑generation cell therapy, potentially reshaping treatment access and cost structures in hematologic cancers. It also signals growing investor confidence in in‑vivo CAR‑T platforms despite early‑stage data.

Key Takeaways

• Lilly offers $3.25B upfront for Kelonia, up to $7B total
• Kelonia's in vivo CAR‑T KLN‑1010 showed MRD‑negative results in four patients
• In vivo CAR‑T avoids ex vivo manufacturing and lymphodepletion
• Lilly's oncology M&A spree includes Centessa, Orna, Ventyx acquisitions
• Oncology remains secondary to cardiometabolic growth but solid‑tumor focus persists

Pulse Analysis

Lilly’s $3.25 billion upfront bid for Kelonia underscores a strategic pivot toward in‑vivo CAR‑T technology, a field that promises to simplify the complex logistics of traditional ex‑vivo cell therapies. By delivering engineered T cells directly into patients, the platform could eliminate costly manufacturing steps and the need for aggressive lymphodepletion, potentially expanding access to life‑saving treatments for multiple myeloma and other blood cancers. Early data from the inMMyCAR study, where all four participants achieved MRD‑negative status, provides a compelling proof‑of‑concept that may attract further investment and accelerate regulatory pathways.

The acquisition fits within Lilly’s broader M&A playbook, which has leveraged cash generated by its dual GIP/GLP‑1 agonists Mounjaro and Zepbound to fund high‑growth oncology assets. Recent deals—including a $7.8 billion bid for Centessa, a $2.4 billion offer for Orna Therapeutics, and a completed $1.2 billion purchase of Ventyx Bio—illustrate a concerted effort to diversify beyond its cardiometabolic stronghold. By securing Kelonia, Lilly not only adds a novel therapeutic modality but also positions itself to compete with peers like BMS and Gilead, who have pursued smaller in‑vivo CAR‑T acquisitions.

Industry analysts view the $7 billion potential valuation as bold, given KLN‑1010’s early‑stage status, yet it reflects a premium placed on platform technology that could disrupt the cell‑therapy market. If Lilly can translate the early signals into larger trials, the in‑vivo approach may lower production costs, shorten time‑to‑patient, and broaden the addressable patient pool. Success would reinforce Lilly’s reputation for strategic reinvestment of its obesity‑diabetes cash flow into high‑margin oncology pipelines, potentially reshaping the competitive dynamics of both sectors.